Recro Pharma (REPH): Phase 3 Data, A Catalyst This Quarter - HC Wainwright

November 14, 2016 7:22 AM EST
Get Alerts REPH Hot Sheet
Price: $7.33 +3.24%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade REPH Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Recro Pharma (NASDAQ: REPH) and expects positive Phase 3 data of IV meloxicam in the abdominoplasty trial to drive meaningful share gains.

On the 3Q earnings call, Recro affirmed that enrollment into the second pivotal trial of IV meloxicam is complete and on track to readout by the year end. As a reminder, this trial is a randomized, multicenter, double-blind, placebo-controlled Phase 3 study (NCT02678286) designed to test IV meloxicam in 200 subjects following "mini" abdominoplasty surgery, a representative soft tissue surgery that is commonly used in pain management trials.

For an analyst ratings summary and ratings history on Recro Pharma click here. For more ratings news on Recro Pharma click here.

Shares of Recro Pharma closed at $8.04 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Earnings, H.C. Wainwright, Ed Arce

Add Your Comment